Sarepta Therapeutics (SRPT)

$67.78 1.17 (1.70%)

16:00 EDT SRPT Stock Quote Delayed 30 Minutes

Positive Spin Isn’t Working for Sarepta Therapeutics

By Josh Enomoto, InvestorPlace Contributor Apr 7, 2021

SRPT stock has some positives going for it but its underlying gene therapy solutions have questions that investors can’t shake.

SRPT Stock Alert: Why Sarepta Therapeutics Stock Is Plunging Today

Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy Drug

5 Top Stock Trades for Tuesday: AAPL, GM, SRPT

Volume:

Previous Close -

Market Cap 5.41B

PE Ratio -7.59

EPS -8.93

Volume (Avg. Vol.) 642,779

Day's Range 67.39 - 68.71

52-Week Range 65.30 - 181.83

Dividend & Yield N/A (N/A)

SRPT Stock Predictions, Articles, and Sarepta Therapeutics News

From InvestorPlace
From the Web

5 Stocks to Buy That Could Double in 2020

By Harriet Lefton, Writer, TipRanks Sep 24, 2019

These are stocks with extremely high potential returns. We are talking about upside potential of over 100%. And that’s not just according to my wild calculations. That’s according to the analysts covering these stocks.

Stock Market Today: Beyond Meat Makes a Friend on Wall Street

By James Brumley, InvestorPlace Feature Writer Aug 20, 2019

Apple's health initiative can't keep key people and Sarepta Therapeutics' CLR are a couple more top news items about the stock market today.

8 Biotech Stocks to Watch After the Q2 Earnings Season

By Chris Lau, InvestorPlace Contributor Aug 20, 2019

Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.

Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook

By Bret Kenwell, InvestorPlace Contributor Jun 28, 2019

The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.

5 Top Stock Trades for Monday: STZ, C, UBER

By Bret Kenwell, InvestorPlace Contributor Jun 28, 2019

STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.

7 Stocks to Buy for Over 20% Upside Potential

By Harriet Lefton, Writer, TipRanks May 20, 2019

If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.

5 Biotech Stocks for a Long-Lived Portfolio

By Chris Lau, InvestorPlace Contributor Apr 30, 2019

Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.

10 A-Rated Stocks the Smart Money Is Piling Into

By Louis Navellier, Editor, Growth Investor Apr 30, 2019

If you follow the smart money, you end up following these stocks to buy. Here's what you should know about each.

8 Genomic Testing Stocks That Can Ease the Sting of Theranos

By James Brumley, InvestorPlace Feature Writer Mar 27, 2019

InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.

Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today

By Karl Utermohlen, InvestorPlace Writer Mar 6, 2019

Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.

Why NOW Is the Time to Buy Gene Therapy Stocks

By InvestorPlace Research Staff Mar 4, 2019

Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.

Why Sarepta Therapeutics Stock Is Starting to Shine Again

By Chris Lau, InvestorPlace Contributor Jan 11, 2019

SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.

7 Rising Healthcare Stocks to Consider

By Chris Lau, InvestorPlace Contributor Oct 29, 2018

Healthcare stocks recovered throughout 2018 but the recent correction in some big names is creating an entry point.

Time to Take Some Profits in Sarepta Therapeutics Stock

By Dana Blankenhorn, InvestorPlace Contributor Aug 29, 2018

Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..

Play The Future of Gene Therapy With These 5 Biotech Stocks

By Aaron Levitt, InvestorPlace Contributor Aug 27, 2018

What's the next big thing in biotech? The answer is gene therapy and these five biotech stocks are leading the way.

7 Strong Buy Stocks With 30%+ Upside Potential

By Harriet Lefton, Writer, TipRanks Aug 22, 2018

According to Wall Street, these 7 stellar strong buy stock picks all boast over 30% upside potential from their current prices.

7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.

By Harriet Lefton, Writer, TipRanks Jun 13, 2018

Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.